Cancer-related fatigue: A practical review

M. P.O. Campos, B. J. Hassan, R. Riechelmann, A. Del Giglio

Research output: Contribution to journalReview article

112 Scopus citations

Abstract

Fatigue is an exceedingly common often treatable problem in cancer patients that profoundly affects all aspects of quality of life. Prevalence estimates have ranged from 50% to 90% of cancer patients overall. After addressing reversible or treatable contributing factors, such as hypothyroidism, anemia, sleep disturbance, pain, emotional distress, climacterium, medication adverse events, metabolic disturbances, or organ dysfunction such as heart failure, myopathy, and pulmonary fibrosis, patients may be screened with a brief fatigue self-assessment tool. All cancer patients should be screened regularly for fatigue. Those with moderate or severe fatigue may benefit from both pharmacologic and nonpharmacologic interventions, while mild fatigue that does not interfere with quality of life can be treated with nonpharmacologic measures alone. Physicians often have insufficient knowledge about fatigue and its treatments or underestimate the impact of fatigue on quality of life, while patients may consider it an unavoidable and untreatable side-effect and fear that reporting it may incite a change toward less aggressive cancer treatment. A practical review may therefore be useful to health care professionals in order to avoid the common barriers to its treatment that exist on the sides of both physicians and patients.

Original languageEnglish (US)
Pages (from-to)1273-1279
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number6
DOIs
StatePublished - 2011

Keywords

  • Cancer
  • Fatigue
  • Review

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Cancer-related fatigue: A practical review'. Together they form a unique fingerprint.

  • Cite this

    Campos, M. P. O., Hassan, B. J., Riechelmann, R., & Del Giglio, A. (2011). Cancer-related fatigue: A practical review. Annals of Oncology, 22(6), 1273-1279. https://doi.org/10.1093/annonc/mdq458